

Limited Submission Funding Opportunities – updated 2/03/23

Please be aware that any grant that brings in less than 20% in indirect costs (IDC) will need to be supplemented up to the 20% equivalent by existing investigator or departmental sundry funds. Resolution of this issue must occur prior to submitting a proposal. Training fellowships from foundations, public charity, and non-profit organizations are excluded from this minimum IDC requirement.

For MGH investigators selected through a competitive process as the institutional nominee for any limited submission funding opportunities, in situations in which the grant will bring in less than 20% indirect cost (IDC), ECOR will cover the IDC gap up to a maximum of \$50,000 per year. In order to optimize the distribution of limited ECOR funds across the MGH research community, it is expected that PIs and departments will work together to cover the remaining IDC shortfall.

This policy is only effective for those limited submission opportunities in which MGH is invited to submit its own nominee(s). This policy does not apply for those limited submission opportunities in which the MGH investigator must apply through HMS.

For further questions, please contact ECOR at ecor@mgh.harvard.edu

We ask that all MGH Investigators interested in applying for any limited submission award submit a Letter of Intent (see detailed instructions below) to the MGH Executive Committee on Research (ECOR) by the deadline indicated for each award to be considered to receive an institutional nomination.

Process

Submit a one- to two-page Letter of Intent (LOI) to the MGH Executive Committee on Research (ECOR) via email to ecor@mgh.harvard.edu. In addition to your LOI, please include an NIH Biosketch.

The letter of intent should include:

1. Name of the Principal Investigator with appropriate contact information
2. A descriptive title of the potential application
3. Brief description of the project
4. Brief description of why you specifically should be selected to receive institutional nomination for this award

In the event that there is more than one MGH investigator interested in applying for a limited submission award, the LOIs will be used to assess candidates and a review and selection process will take place.

If there is a limited submission funding opportunity you do not see listed below or you have any additional questions, please let us know at ecor@mgh.harvard.edu.

CURRENT OPPORTUNITIES

1. Enhancing Telehealth Strategies to Support Retention and Adherence to Antiretroviral Therapy (ART)

Telehealth services such as TeleART are becoming more widely implemented; however, to date, there is a dearth of evidence of effectiveness of TeleART for antiretroviral therapy (ART) adherence and retention in HIV care in the U.S. The purpose of the research supported by this Notice of Funding Opportunity (NOFO) is to evaluate the effectiveness of an enhanced telehealth program to improve adherence to ART, while also exploring the “implementability” of enhanced telehealth practice into routine care using a hybrid effectiveness-implementation Page 2 of 64 research design. The study should: 1) evaluate the effectiveness of an enhanced telehealth program for maintenance of HIV medication adherence among clinically stable people with HIV (PWH) and 2) identify potential implementation facilitators and

Limited Submission Funding Opportunities – updated 2/03/23

challenges by evaluating the delivery of these strategies. Furthermore, the study should evaluate the cost and costeffectiveness of providing telehealth to patients on ART, and evaluate program enhancements that include, but may not be limited to, biospecimen sample self-collection and the use of specialized staff such as community health workers and patient navigators.

This enhanced telehealth program should focus on groups disproportionately affected by HIV and other persons for whom social determinants of health (e.g., stigma, discrimination, poverty, and low socioeconomic status) limit their engagement in HIV care and treatment. Specifically, African American cis-gender women, and/or Black or Hispanic/Latino gay, bisexual and other men who have sex with men, and/or transgender women, are groups of interest. The research supported by this NOFO should support Ending the HIV Epidemic in the U.S. (EHE) goals and should build on CDC's Division of HIV Prevention telehealth activities.

MGH LOI Deadline: 2/06/23

Sponsor LOI Deadline: 2/17/23

Sponsor Application Deadline: 3/17/23

[Learn more](#)

2. Expanding Rapid Initiation of Antiretroviral Therapy in Non-traditional Settings: Emergency Department

The purpose of this Notice of Funding Opportunity (NOFO) is to support implementation research on the rapid or immediate initiation of HIV antiretroviral therapy (ART) for persons newly diagnosed with HIV or for persons with HIV (PWH) returning to care in emergency department (ED) settings. The rapid ART model, defined as immediate diagnosis, linkage to care, and ART initiation on the same day as a new HIV diagnosis or return to care, should offer an accelerated entry into HIV medical care. Rapid ART confers a higher rate of engagement in care, reduces the time to viral suppression, and improves morbidity and mortality in PWH. The ED offers a unique setting to immediately engage with patients who are not accessing HIV care services. The implementation research supported by this funding will deploy rapid ART models in ED settings and evaluate acceptability, perceived barriers and facilitators, feasibility, sustainability, and HIV care continuum outcomes. Applied research resulting from this funding is expected to decrease HIV infections and quickly achieve viral suppression among PWH. This research is aligned with the HIV National Strategic Plan (2022-2025) and the Ending the HIV Epidemic in the U.S. (EHE) initiative "Treat" Pillar.

MGH LOI Deadline: 2/08/23

Sponsor LOI Deadline: 2/21/23

Sponsor Application Deadline: 3/22/23

[Learn more](#)

3. Environmental Health Sciences Core Centers (EHSCC) (P30 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) invites grant applications for Environmental Health Sciences Core Centers (EHS CC). As intellectual hubs for environmental health science research, the EHS CC is expected to be the thought leaders for the field and advance the goals of the NIEHS Strategic Plan (<http://www.niehs.nih.gov/about/strategicplan/>). The Core Centers provide critical research infrastructure, shared facilities, services and/or resources, to groups of investigators conducting

Limited Submission Funding Opportunities – updated 2/03/23

environmental health sciences research. An EHS CC enables researchers to conduct their independently-funded individual and/or collaborative research projects more efficiently and/or more effectively. The overall goal of an EHS CC is to identify and capitalize on emerging issues that advance understanding of the relationships among environmental exposures, human biology, and disease. The EHS CC supports community engagement and translational research as key approaches to improving public health.

MGH LOI Deadline: 2/28/23

NIH LOI Deadline: 3/19/23

NIH Application Deadline: 4/19/23

[Learn more](#)

4. Autoimmunity Centers of Excellence, Basic Research Program (U19 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications to participate in the [NIAID Autoimmunity Centers of Excellence \(ACE\)](#), a cooperative network intended to improve the understanding, prevention, and treatment of autoimmune diseases. The ACE was founded on the premise that collaborations among basic and clinical scientists can accelerate both fundamental and applied research. The ACE combines Basic and Clinical research programs. This FOA solicits applications for the Basic research program; a companion FOA solicits applications for the Clinical research program. Members of the Basic research program will conduct innovative studies of human autoimmunity within Principal, Pilot, and Collaborative Projects. Members of the Basic and Clinical ACE will work together to design and conduct studies of autoimmune disease pathogenesis and mechanisms of action of immune-modulating interventions being tested in ACE clinical trials.

MGH LOI Deadline: 3/20/23

NIH LOI Deadline: 4/19/23

NIH Application Deadline: 5/19/23

[Learn more](#)

5. Autoimmunity Centers of Excellence, Clinical Research Program (UM1 Clinical Trial Required)

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications to participate in the [NIAID Autoimmunity Centers of Excellence \(ACE\)](#), a cooperative network intended to improve the understanding, prevention, and treatment of autoimmune diseases. The ACE program was founded on the premise that collaborations among basic and clinical scientists can accelerate both fundamental and applied research. The ACE combines Basic and Clinical research programs. This FOA solicits applications for the Clinical research program; a companion FOA solicits applications for the Basic research program. Members of the Clinical research program will conduct innovative studies of human autoimmunity within Clinical and Collaborative Projects. Members of the Basic and Clinical ACE will work together to design and conduct studies of autoimmune disease pathogenesis and mechanisms of action of immune-modulating interventions being tested in ACE clinical trials.

MGH LOI Deadline: 3/20/23

NIH LOI Deadline: 4/19/23

NIH Application Deadline: 5/19/23

[Learn more](#)